Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short | Global News Avenue

incyte(Incy) Stocks are one of the largest sellers S&P 500 No analyst estimates were made on Monday after the drugmakers sold their major drug sales in the fourth quarter and forecasts in 2025.

Incyte’s fourth-quarter sales were $1.18 billion, up 16% year-on-year, and is estimated to be the highest estimate for Alpha, with its two largest drugs (Jakafi and Opzelura sales) rising 11% to $773.1 million respectively, 48 % to $161.6 million.

The company has been adjusted Earnings per share (EPS) The $1.43 price rose from $1.06 last year, but 10 cents lower than expected.

The sales prospects for the largest drugs are disappointing

Incyte’s outlook for Jakafi and Opzelura sales is also lower than expected. The company expects Jakafi’s sales to prevent overproduction of red blood cells and will bring in $2.925 billion to $2.975 billion in sales in 2025 and sell it. forecast Between $630 million and $670 million.

Analysts entered Monday and expected sales of the two drugs to be $3.34 billion and $672.2 million, respectively.

Incyte shares fell more than 6% on Monday afternoon, but have still grown about 20% over the past 12 months.